## PII Q3 2020-21

ld	Resear ch Ethics Commi ttee Refere nce Numbe r	Integrat ed Resear ch Applica tion System Numbe r	Name of Trial	First Particip ant Recruit ed?	Date of First Particip ant Recruit ed	Duratio n betwee n Date Site Selecte d and Date Site Confir med	Duratio n betwee n Date Site Confir med and First Particip ant Recruit ed	Duratio n betwee n Date Site Selecte d and First Particip ant Recruit ed	Date Site Invited	Date Site Selecte d	HRA Approv al Date	Date Site Confir med By Sponso r	Date Site Confir med	Non- Confir mation Status	Date Site Ready To Start	Reason s for Delay	Comme nts	Reason s for delay corresp ond to:
176886	20/YH/0 004	272789	Long- Term Safety and Efficacy of BMS- 986165 in Subject s with Psoriasi s	Yes	20/08/2 020	15	21	36	02/10/2 019	15/07/2 020	09/06/2 020	23/07/2 020	30/07/2 020	Please Select	06/08/2 020	D - Sponso r Delays	confirm ation of C&C issued 30/07/2 020, sponsor replied that they should have us greenlig hted by the end of next week due to internal process es. 06/08/2 020 approva I receive d to recruit.	Sponso r
176887	19/WA/ 0365	261306	CAIN45 7M2301 E1 (SUN Extensi on) Secukin umab in hidrade nitis suppura tiva	Yes	03/09/2 020	3	14	17	16/10/2 019	17/08/2 020	23/01/2 020	19/08/2 020	20/08/2 020	Please Select	01/09/2 020	D - Sponso r Delays	Had to wait for sponsor greenlig ht, they would not issue until IMP receive d at site.	Sponso r

17	6888	20/SS/0 004	262376	LPS154 97	No	4		18/03/2 019	07/09/2 020	09/07/2 020	07/09/2 020	11/09/2 020	Please Select	22/10/2 020	J - Other	SIV planned for April 2020 but had to be postpon ed due to COVID 19 pandem ic.	Neither
177	6889	19/YH/0 400	271539	A Multice nter, Double-blind, Placebo - controll ed, Rando mized Withdra wal, Parallel Group Study of Patirom er for the Manage ment of Hyperk alemia in Subject s Receiving Renin-Angiote nsin-Aldoster one System Inhibitor (RAASi) Medicat ions for the Treatm ent of Heart Failure	No			17/07/2 019	19/09/2	09/01/2			Please Select		D - Sponso r Delays E - Staff availabil ity issues J - Other	SIV not available until after 15/04/2 020 as spec by sponsor . SIV delayed due to COVID 11/08/2 020 SIV postpon ed due to PI unavail ability due to personn el reasons . to be rebooked. SIV held 10/09/2 020 - pharma cy queries to resolve. 24/09/2 020 so can now issue C&C 28/10/2 020	Both

			(DIAMO ND)														STILL WAITIN G FOR GREEN LIGHT FROM SPONS OR.	
177681	18/YH/0 483	237481	BIOST REAM HF: Observ ation of clinical routine care for heart failure patients implant ed with BIOTR ONIK CRT devices	Yes	05/03/2 020	15	7	22	19/09/2 019	12/02/2 020	14/10/2 019	17/02/2 020	27/02/2 020	Please Select	03/03/2 020	D - Sponso r Delays	delay with receivin g sponsor greenlig ht to start recruitm ent.	Sponso r
177682	19/LO/1 035	264950	G PLUS - A Phase 3b, Multice nter, Interven tional, Rando mized, Placebo - controll ed Study Investig ating the Efficacy and Safety of Guselku mab for the Treatm ent of Palmopl antar non- Pustular	No		4			11/01/2 019	06/01/2 020	29/07/2 019	12/12/2 019	10/01/2 020	Please Select	20/01/2 020	D - Sponso r Delays E - Staff availabil ity issues	December 2019 both CT pharma cists off sick. CRA off sick until 09/01/2 020. 17/01/2 020 Drs not complet ed IWRS training so sponsor could not issue green light to comme nce recruitment	Both

			Psoriasi s G PLUS - A Phase 3b, Multice nter, Interven tional, Rando mized, Placebo - controll ed Study Investig ating the Efficacy and Safety of Guselku mab for the Treatm ent of Palmopl antar Psoriasi s													
177807	19/YH/0 158	262107	TRANSI TION	No	42		14/01/2 019	16/01/2 020	26/07/2 019	18/02/2 020	27/02/2 020	Please Select	03/03/2 020	H - Contrac ting delays	followin g SIV on 13/02/2 020 CTA had to be amende d to reduce the recruitm ent target.	Both
177808	19/NE/0 328	270912	M19- 164 Plaque Psoriasi s	No	0		24/06/2 019	05/02/2 020	19/11/2 019	20/12/2 019	05/02/2 020	Please Select	10/02/2 020	D - Sponso r Delays	SIV booked for Nov but had to be delayed	Sponso r

																	until end of Jan as approva Is not receive d. SIV booked for 30/01/2 020. Sponso r won't issue green light until sub-Inv in post. 10/02/2 020 green light receive d.	
178348	20/EM/ 0198	283686	ARCAD IA Trial_S GS1656 .201_V 1.0	Yes	03/11/2 020	5	21	26	09/06/2 020	08/10/2 020	31/07/2 020	06/10/2 020	13/10/2 020	Please Select	29/10/2 020	J - Other	Waiting for pharma cy green light - due to e- prescrib ing and dispensi ng of the drug at weeken ds	NHS Provide r
178349	19/WM/ 0336	270551	Zanubr utinib + Rituxim ab vs Benda mustine + Rituxim ab for untreate d MCL	No					14/06/2 019	04/11/2 020	27/01/2 020	04/11/2 020		Please Select		J - Other	March 2020 - study set-up suspen ded due to COVID 19 pandem ic. August 2020 - set-up re-	Both

															started. Delays due to pandem ic restricti ons and added pressur es on pharma cy and delivery teams. Nov 2020 sponsor sent signed CTA as wanted it before SIV. As per HRA guidelin es, this is not feasible , hence delay with DGH final signatur e. 26/01/2 021 still awaiting pharma cy greenlig ht. Contrac	
178350	20/SC/0 031	275229	A Phase 3 study to assess Nemoliz umab in Atopic Dermati tis	No	52		25/10/2 019	24/11/2 020	27/08/2 020	24/11/2 020	15/01/2 021	Please Select	25/01/2 021	H - Contrac ting delays	t can't be issued until after greeligh t from pharma cy - pharma cy SIV is	Both

									30.11.2	
									020 and	
									have	
									informe	
									al rese	
									d me	
									that	
									greenlig	
									ht may	
									not be	
									given that	
									that	
									week as	
									request	
									ed by	
									eu by	
									sponsor	
									. I have	
									emailed	
									sponsor	
									on	
									numero	
									us	
									occasio	
									ns	
									saving	
									saying thet we	
									can't	
									icouc	
									issue FE CTA	
									FECIA	
									until	
									after	
									pharma	
									pharma cy	
									greenlig	
									ht and SIV and	
									SIV and	
									it will be	
									goven	
									as part	
									as part of	
									confirm	
									otion of	
	J								COC	
									ation of C&C. 07.12.2	
l								l	07.12.2	
	J								020	
									Pharma	
									cy SIV	
									cy SIV complet ed	
l								l	ed	
	J								04.12.2 020 and	
									020 and	
									main	
									main SIV to	
									be	
	J								rearran	
									and	
									ged -	
									pharma	

															cy have informe d the sponsor that greenlig ht may not be given unti	
178351	19/NE/0 215	234453	Myelom a XIV (FiTNEs s)	No	0		18/05/2 018	13/10/2 020	07/11/2 019	26/01/2 021	13/10/2 020	Please Select	01/03/2 021	J - Other	opening suspen ded due to COVID. a/w further update from sponsor . Set-up comme nced, further delays due to pharma cy capacity .	Both